Value of venous thromboembolism prophylaxis by enoxaparin with anti-factor Xa trough concentration monitoring in surgical care
Main Article Content
Keywords
References
1. Scrimenti A, Seabury RW, Miller CD, Ruangvoravat L, Darko W, Probst LA, Cwikla GM. Pharmacist recommendations for prophylactic enoxaparin monitoring and dose adjustment in trauma patients admitted to a surgical intensive care unit. Pharmacy Practice. 2019;17(4):1541. https://doi.org/10.18549/PharmPract.2019.4.1541
2. Ko A, Harada MY, Barmparas G, Chung K, Mason R, Yim DA, Dhillon N, Margulies DR, Gewertz BL, Ley EJ. Association between enoxaparin dosage adjusted by anti–factor Xa trough level and clinically evident venous thromboembolism after trauma. JAMA Surg. 2016;151(11):1006-1013. https://doi.org/10.1001/jamasurg.2016.1662
3. Singer GA, Riggi G, Karcutskie CA, Vaghaiwalla TM, Lieberman HM, Ginzburg E, Namias N, Lineen EB. Anti-Xa–guided enoxaparin thromboprophylaxis reduces rate of deep venous thromboembolism in high-risk trauma patients. J Trauma Acute Care Surg. 2016;81(6):1101-1108. https://doi.org/10.1097/TA.0000000000001193
4. Ohta H, Miyake T, Shimuzu T, Sonoda H, Ueki T, Kaida S, Yamaguchi T, Iida H, Tani M. The impact of pharmacological thromboprophylaxis and disease-stage on postoperative bleeding following colorectal cancer surgery. World J Surg Oncol. 2019 Jun 27;17(1):110. https://doi.org/10.1186/s12957-019-1653-1
5. Sun G, Wu J, Wang Q, Liang Q, Jia J, Cheng K, Sun G, Wang Z. Factor Xa inhibitors and direct thrombin inhibitors versus low-molecular-weight heparin for thromboprophylaxis after total hip or total knee arthroplasty: A Systematic Review and Meta-Analysis. J Arthroplasty. 2019;34(4):789-800. https://doi.org/10.1016/j.arth.2018.11.029
2. Ko A, Harada MY, Barmparas G, Chung K, Mason R, Yim DA, Dhillon N, Margulies DR, Gewertz BL, Ley EJ. Association between enoxaparin dosage adjusted by anti–factor Xa trough level and clinically evident venous thromboembolism after trauma. JAMA Surg. 2016;151(11):1006-1013. https://doi.org/10.1001/jamasurg.2016.1662
3. Singer GA, Riggi G, Karcutskie CA, Vaghaiwalla TM, Lieberman HM, Ginzburg E, Namias N, Lineen EB. Anti-Xa–guided enoxaparin thromboprophylaxis reduces rate of deep venous thromboembolism in high-risk trauma patients. J Trauma Acute Care Surg. 2016;81(6):1101-1108. https://doi.org/10.1097/TA.0000000000001193
4. Ohta H, Miyake T, Shimuzu T, Sonoda H, Ueki T, Kaida S, Yamaguchi T, Iida H, Tani M. The impact of pharmacological thromboprophylaxis and disease-stage on postoperative bleeding following colorectal cancer surgery. World J Surg Oncol. 2019 Jun 27;17(1):110. https://doi.org/10.1186/s12957-019-1653-1
5. Sun G, Wu J, Wang Q, Liang Q, Jia J, Cheng K, Sun G, Wang Z. Factor Xa inhibitors and direct thrombin inhibitors versus low-molecular-weight heparin for thromboprophylaxis after total hip or total knee arthroplasty: A Systematic Review and Meta-Analysis. J Arthroplasty. 2019;34(4):789-800. https://doi.org/10.1016/j.arth.2018.11.029
Article Sidebar
Published
Feb 17, 2020
Article Details
How to Cite
1.
Value of venous thromboembolism prophylaxis by enoxaparin with anti-factor Xa trough concentration monitoring in surgical care. Pharm Pract (Granada) [Internet]. 2020 Feb. 17 [cited 2023 Dec. 6];18(1):1808. Available from: https://pharmacypractice.org/index.php/pp/article/view/1808
Section
Letters to the Editor
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.